Find in Library

<b>Background</b>: <i>KRAS</i> G12D mutation subtype is present in over 40% of pancreatic ductal adenocarcinoma (PDAC), one of the leading global causes of cancer death. This retrospective cohort study aims to investigate whether detection of the <i>KRAS</i> G12D mutation subtype in PDAC patients is a determinant of prognosis across all stages of disease. <b>Methods</b>: We reviewed the medical records of 231 patients presenting with PDAC at a large tertiary hospital, and compared survival using the Kaplan Meier, log-rank test and Cox proportional hazards regression model. <b>Results</b>: <i>KRAS</i> G12D mutation subtype was not significantly associated with poorer survival compared across the whole population of PDAC patients (<i>p</i> = 0.107; HR 1.293 95% CI (0.946–1.767)). However, <i>KRAS</i> G12D patients who were resectable had a shorter median survival time of 356 days compared to all other genotypes (median survival 810 days) (<i>p</i> = 0.019; HR 1.991 95% CI (1.121–3.537)). <b>Conclusions</b>: <i>KRAS</i> G12D patients who were resectable at diagnosis had shorter survival compared to all other PDAC patients. These data suggest that <i>KRAS</i> G12D may be a clinically useful prognostic biomarker of PDAC.